HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
La Chaux-de-Fonds, Switzerland , Dec. 09, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announced today that they have entered into an exclusive, worldwide license agreement with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K-delta gamma inhibitor and its closely related compounds for various indications.
Under the terms of the agreement, Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sales milestones payments. In addition Rhizen is also eligible to receive tiered royalties on annual nets sales.
The lead compound is a novel, potent, and selective dual PI3K-delta gamma inhibitor with demonstrated anti-inflammatory and immuno-modulatory activity in pre-clinical systems and models representative of respiratory diseases. With a favorable ADME and PK profile and high therapeutic index in animals, the inhaled dual PI3K-delta gamma inhibitor holds promise in the treatment of human airway disorders.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
Contact: [email protected]
